Our leadership team have broad and extensive experience in cell therapy, regenerative medicine and drug development.
Read BioDr. Michael Leek, Founder and Chief Executive
Read BioAngela Scott, Co-founder and Chief Operating Officer
Read BioMartin Thorp, Chief Financial Officer
Read BioDr. Alan Clark, Executive Chairman
Read BioProf. John Anderson, Scientific and Medical Director
Toby Rintoul, Senior Director of Finance
Dorothy Lister, Senior Director of Operations
Dr. Tomasz Zaremba, Director of Clinical
Dr. Owain Millington, Director of Research
Dr. Cameron Mackenzie, Director of Business Development
Michael has 30 years’ experience in regenerative medicine, during which he progressed 10 different cell-based products from the laboratory into clinic. As co-founder, he was jointly responsible for moving Intercytex from a pre-clinical research company, to an AIM-listed biotech with several cell therapy products in the clinic. He has extensive GMP manufacture expertise which includes management of several FDA/EMEA/MHRA licensed GMP facilities. Additionally, Michael has clinical, regulatory and logistic expertise and he has directly raised over $60m in equity and grant funding. In 2017, Michael received the 'Scottish Life-Sciences Entrepreneurial Business Leadership' award for 2016-2017.
Michael is also a Fellow of the Royal Society of Medicine and Honorary Lecturer at the University of Aberdeen, School of Medical Sciences.
Angela has 37 years in oncology research and regenerative medicine, was part of the team that cloned ‘Dolly the Sheep’, and has designed, built and commissioned several GMP manufacturing facilities. She manufactured product for the UK’s ‘first-in-man’ stem cell trial (PISCES – ReNeuron), and has held MHRA -MIA and -IMP licenses for several cell therapy products.
Angela has a BSc in Life Sciences and over 30 years’ hands on experience in stem cell research and the application of cutting edge cell therapy. Angela has contributed to the transition of several cell therapy products from bench to bedside.
At TC BioPharm, Angela has wide-ranging responsibilities including managing GMP manufacture of clinical products, Quality Control and Assurance and managing product development.
Martin is the Chief Financial Officer of TC BioPharm. Martin has been a director of TC BioPharm since 2015 and was an early stage investor.
Martin is also the founder and chairman of a life science financial advisory firm, NCL Corporate Finance, headquartered in London and has representation in New York, Beijing and Shanghai. Martin is also a founding director (non-executive) of a life science investment firm NCL Technology Ventures.
Martin qualified as a Chartered Accountant with Arthur Andersen & Co in London and became a partner in that firm and a Fellow of the Institute of Chartered Accountants in England and Wales. He pioneered the development of corporate finance and transaction-led services by international ‘accounting’ firms when at Arthur Andersen, becoming the founder and global managing partner of Arthur Andersen’s global corporate finance firm (1000 professionals in 35 countries with over $1bn in annual revenues). That firm was responsible for billions of dollars of transaction advisory and lead execution services from M&A to IPOs and restructurings. Amongst Martin's clients were two start-ups to FTSE 100 listed companies. Martin has been involved in several leading edge private and public technology companies, as a director, adviser and/or investor.
Alan is the Executive Chairman of TC BioPharm. Alan has over 20 years’ experience in biotech and pharma with a strong track record in strategy, due diligence and licensing. Alan has a broad range of experience in drug discovery and development across multiple therapeutic indications. As an independent consultant, Alan has worked with a large number of global clients including SMEs, investors and large pharma and has extensive experience in operational and business development roles, building and managing high-performing research teams and external collaborations. Alan has a portfolio interest in a number of biotech companies at board level.
Prof. Anderson is the Scientific and Medical Director at TC BioPham. As a distinguished clinical investigator and academic researcher, Prof. Anderson’s breadth of expertise and experience strengthens the leadership team and contributes to the company mission of improving patient health and Quality of Life. Prof. Anderson leads research into novel immunotherapies with a focus on childhood solid cancers at the UCL Great Ormond Street Institute of Child Health, where he is Professor of Experimental Paediatric Oncology. He is also the Chief Investigator of a Cancer Research UK sponsored trial of anti-GD2 CAR-T cells for neuroblastoma patients.